Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Finasteride is a synthetic 4-azasteroid and a selective inhibitor of the type II and III isoforms of the enzyme 5α-reductase. By inhibiting this enzyme in tissues such as the prostate gland and hair follicles (but not significantly in other tissues), it blocks the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen responsible for prostate growth and male pattern hair loss. This results in reduced DHT levels by about 65–70% systemically and up to 80–90% within the prostate gland. Clinically approved indications include benign prostatic hyperplasia (BPH) at a dose of 5 mg daily (marketed as Proscar) and male pattern hair loss at a dose of 1 mg daily (marketed as Propecia). The drug was originally developed by Merck[1][2][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on finasteride.